The Swedish Medical Products Agency, Läkemedelsverket, is investigating the deaths of two people who had recently received the AstraZeneca Covid-19 vaccine.
Late Thursday, the European Medicines Agency announced it was safe to continue using Astra Zeneca’s vaccine.
Läkemedelsverket comments that “so far, we have neither been able to prove nor disprove a connection between these deaths and the vaccine.”
Anders Tegnell: Sweden chooses to pause vaccination [with AstraZeneca] due to new signals about suspected side effects in connection with the vaccine.
Now we have discovered another type of symptom which is a slightly more serious disorder in the blood system and which can cause both clots and bleeding, says Anders Tegnell.
We have discovered it in slightly younger people as well, so it is a different type of signal that is being investigated.
The nurse from the state hospital in Zwettl was admitted to the intensive care unit of the Vienna General Hospital last weekend. The 49-year-old then died as a result of severe coagulation disorders. In order to clarify the cause of death of the nurse, an autopsy will be carried out at the Vienna General Hospital. The deceased had received the first dose of the Covid-19 vaccine from AstraZeneca in Lower Austria ten days before admission to the intensive care unit.
A 35-year-old colleague of the deceased was also in inpatient treatment in the internal department at the Zwettl State Hospital after her vaccination.
Stefano Paternò, a 43-year-old soldier serving in Sircusa, Italy, died yesterday morning of a cardiac arrest in his home . The soldier the day before had undergone the first dose of vaccine from batch ABV2856, the one for which the Italian Medicines Agency AIFA asked for a stop.
On the case the Prosecutor of Syracuse has opened an investigation and ordered an autopsy. About ten people would be registered in the register of suspects, the entire distribution chain of the vaccine from the AstraZeneca company that produces it, up to the medical staff of the military hospital who took care of the inoculation. The charge for all is of manslaughter.
Paternò was a non-commissioned officer in the Navy in Augusta. Two days ago he had undergone the first dose of vaccine from the same batch of which today Aifa requested the seizure.
This is the story of his wife: “My husband had had the vaccine on Monday morning and in the afternoon he returned home and was fine. Around 7.30 pm he felt tremors, he was cold and measuring his temperature, he had a fever of 39. He took a tachypirna and the fever had gone down, he felt better and we went to sleep around 11 pm. In the night, however, I was awakened by his moans: he was shaking, wobbling in bed and breathing heavily “. Caterina Arena remembers having “immediately called 118 and in a very short time the doctors started to give him help in every way, even the heart massage, but there was nothing to do and the doctors could not understand from what that state had been determined. ” The woman then points out that “many of Stefano’s colleagues who have been vaccinated have had a high fever”.
The Public Prosecutor ordered the seizure of the ‘indicted’ lot in the possession of the ASP of Syracuse and reported the case to the AIFA. Tomorrow an autopsy will be performed on the victim’s body at the Cannizzaro hospital in Catania, while the are expected in the Etna capital inspectors sent by the Minister of Health .
Scientists advising the World Health Organisation (WHO) have recommended the use of the Oxford-AstraZeneca Covid-19 vaccine in all adults – including those aged over 65 – after a number of countries opted not to adminster the jab to that group.
The WHO’s Strategic Advisory Group of Experts (Sage) on Immunisation issued interim recommendations on the vaccine, saying the jab could be given to people aged 18 and above “without an upper age limit”.
“Data from our trials of the ChAdOx1 vaccine in the United Kingdom indicate that the vaccine not only protects against the original pandemic virus, but also protects against the novel variant, B.1.1.7”
The Oxford University researchers who developed the ChAdOx1-nCoV 19 vaccine have found that it remains effective against one of the new variants of the disease.
The preprint also describes recent analysis showing that vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a reduced transmission of the disease.
Andrew Pollard, Professor of Paediatric Infection and Immunity, and Chief Investigator on the Oxford vaccine trial, said:
‘Data from our trials of the ChAdOx1 vaccine in the United Kingdom indicate that the vaccine not only protects against the original pandemic virus, but also protects against the novel variant, B.1.1.7, which caused the surge in disease from the end of 2020 across the UK.’
Sarah Gilbert, Professor of Vaccinology, and Chief Investigator on the Oxford vaccine trial, said:
‘All viruses accumulate mutations over time, and for influenza vaccines there is a well-known process of global viral surveillance, and selection of strains for an annual update of the vaccines.’
Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)
Germany’s vaccine commission STIKO said on Thursday that AstraZeneca’s COVID-19 jab should only be administered to people aged 64 and under. The panel of medical experts cited a lack of data regarding the vaccine’s effectiveness for older people. “There is currently insufficient data to assess the efficacy of the vaccine for persons aged 65 years and older,” the scientific committee said in the resolution made available by the German Health Ministry. “The AstraZeneca vaccine, unlike the mRNA vaccines, should only be offered to people aged 18-64 years at each stage,” it added.